2021
75 Acute and Chronic Hepatitis
Fawaz R, Jonas M. 75 Acute and Chronic Hepatitis. 2021, 819-837.e6. DOI: 10.1016/b978-0-323-67293-1.00075-x.Peer-Reviewed Original ResearchChronic hepatitisLiver biopsyHepatocellular carcinomaHepatitis B virus infectionAcute hepatitis CChronic hepatitis BB virus infectionPerinatal transmission rateGrade of inflammationAutoimmune hepatitisJaundice 3Transplantation 2Hepatitis CHepatitis BClinical courseHepatitis ANonalcoholic steatohepatitisHistologic featuresPersistent elevationViremia levelsPrimary indicationInfection 5Hepatic damageFamily historyVirus infection
2019
Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B
Yarovinsky TO, Mason SW, Menon M, Krady MM, Haslip M, Madina BR, Ma X, Moshkani S, Chiale C, Pal AC, Almassian B, Rose JK, Robek MD, Nakaar V. Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B. IScience 2019, 21: 391-402. PMID: 31704650, PMCID: PMC6889364, DOI: 10.1016/j.isci.2019.10.040.Peer-Reviewed Original ResearchHepatitis B virusChronic hepatitis BHepatitis BSerum HBV surface antigenVirus-like vesiclesLiver HBV RNAPersistent HBV replicationHBV surface antigenImmune exhaustionChronic hepatitisHBV antigensHBV infectionBooster immunizationCD8 TChronic modelHBV replicationImmunotherapeutic approachesLiver injuryNaive miceHBV RNAB virusCurrent treatmentSurface antigenUnmet needMultiple antigensLong-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome
Awadie H, Khoury J, Zohar Y, Yaccob A, Veitsman E, Saadi T. Long-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome. Rambam Maimonides Medical Journal 2019, 10: e0020. PMID: 31335311, PMCID: PMC6649775, DOI: 10.5041/rmmj.10373.Peer-Reviewed Original ResearchHypereosinophilic syndromeIdiopathic hypereosinophilic syndromeLiver involvementLong-term follow-upIsolated liver involvementSolid organ involvementRare systemic diseaseEnd-organ damageIntensive immunosuppressive treatmentAdvanced liver failureHigher eosinophil countsEosinophilic hepatitisImmunosuppressive treatmentChronic hepatitisLiver dysfunctionOrgan involvementLiver biopsyLiver failureEosinophil countOrgan damageRare presentationSystemic diseaseFollow-upAppropriate treatmentLow dose
2018
Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns
Sigel C, Drill E, Zhou Y, Basturk O, Askan G, Pak L, Vakiani E, Wang T, Boerner T, Do R, Simpson A, Jarnagin W, Klimstra D. Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns. The American Journal Of Surgical Pathology 2018, 42: 1334-1345. PMID: 30001234, PMCID: PMC6657522, DOI: 10.1097/pas.0000000000001118.Peer-Reviewed Original ResearchMeSH KeywordsAgedBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorBiopsyCholangiocarcinomaDatabases, FactualFemaleHumansImmunohistochemistryImmunophenotypingIn Situ HybridizationMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPhenotypeProgression-Free SurvivalRetrospective StudiesConceptsPT stageIntrahepatic cholangiocarcinomaSmall ductsAssociated with mucin productionCA19-9 stainingRecurrence-free survivalResected intrahepatic cholangiocarcinomaPrimary sclerosing cholangitisAssociated with subtypesRNA in situ hybridizationPositive tumorsPerineural invasionPeriductal infiltrationHistological typeFrequent alcohol useSclerosing cholangitisImmunophenotypic characteristicsS100P expressionExtracellular mucinChronic hepatitisHistologic associationDuct patternMultivariate analysisRisk factorsMucin productionHistologic features of autoimmune hepatitis: a critical appraisal
Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBiopsyChildChild, PreschoolDatabases, FactualEmperipolesisFemaleHepatitis C, ChronicHepatitis, AutoimmuneHepatocytesHumansKupffer CellsLiverLiver CirrhosisLymphocytesMaleMiddle AgedPlasma CellsPredictive Value of TestsReproducibility of ResultsRetrospective StudiesSeverity of Illness IndexYoung AdultConceptsProminent plasma cellsAutoimmune hepatitisHistologic featuresPlasma cellsInflammatory gradePortal tractsScoring systemInitiation of therapySeverity of hepatitisDifferent control groupsChronic hepatitisHepatitis CFibrosis stageStudy groupDisease processHepatitisControl groupHyaline globulesFurther studiesPatientsTractCritical appraisalCellsGradeTypical features
2015
Knockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway
Shrivastava S, Devhare P, Sujijantarat N, Steele R, Kwon Y, Ray R, Ray R. Knockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway. Journal Of Virology 2015, 90: 1387-1396. PMID: 26581990, PMCID: PMC4719613, DOI: 10.1128/jvi.02383-15.Peer-Reviewed Original ResearchConceptsHepatitis C virusInfectious hepatitis C virusInnate immune responseHCV releaseImmune responseInhibition of HCVVirus-infected hepatocytesExosomal pathwayKnockdown cellsExosome markers CD63Infectious virus particlesBST-2 geneChronic hepatitisRole of autophagyHCV RNALiver cirrhosisHCV pathogenesisC virusInfected hepatocytesViral persistenceHepatocellular carcinomaHCV assemblyMajor causeVirus transmissionPrecise mechanism
2014
Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients
Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Re V. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients. Clinical Infectious Diseases 2014, 58: 1449-1458. PMID: 24569533, PMCID: PMC4001286, DOI: 10.1093/cid/ciu097.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusAdvanced hepatic fibrosisHuman immunodeficiency virusHepatitis C virusAlcohol use categoriesAlcohol-related diagnosesHIV/HCV-coinfected patientsHepatic fibrosisAlcohol consumptionNonhazardous drinkingBinge drinkingHIV/HCV groupAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireVeterans Aging Cohort StudyFIB-4 indexAging Cohort StudyCross-sectional studyHCV groupHCV statusHIV-InfectedUninfected participantsChronic hepatitisUninfected patientsCohort studyLiver disease
2011
IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B
Publicover J, Goodsell A, Nishimura S, Vilarinho S, Wang ZE, Avanesyan L, Spolski R, Leonard WJ, Cooper S, Baron JL. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. Journal Of Clinical Investigation 2011, 121: 1154-1162. PMID: 21393863, PMCID: PMC3049376, DOI: 10.1172/jci44198.Peer-Reviewed Original ResearchConceptsIL-21 productionImmune responseHBV infectionIL-21Viral clearanceYoung miceAdult miceHepatic immune responseAge-dependent outcomesIL-21 receptorB cell responsesAge-dependent effectivenessHuman hepatitis BChronic hepatitisHBV antigensHepatitis BYounger patientsLiver diseaseAntigen persistenceChronic infectionTherapeutic augmentationMajor human pathogenMouse modelBlood samplesAnimal models
2008
Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors
Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. International Journal Of Infectious Diseases 2008, 13: 9-19. PMID: 18835208, PMCID: PMC2651958, DOI: 10.1016/j.ijid.2008.06.019.Peer-Reviewed Original ResearchConceptsHepatitis C antibodyHepatitis CHepatitis BRisk factorsAntigen prevalenceHigh burdenC antibodyActive hepatitis BChronic hepatitis CBlood product transfusionHigh-risk subgroupsHigh-risk populationNational prevalence estimatesMode of transmissionWorld's highest burdenUnsafe bloodChronic hepatitisProduct transfusionLiver failurePediatric populationHigh prevalenceHepatocellular carcinomaNeedle usePrevalence estimatesHealthy adults
2007
Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus
Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 18187-18192. PMID: 17991774, PMCID: PMC2084318, DOI: 10.1073/pnas.0708968104.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis B viral infectionB virusImmune responseAcute hepatitisNKT cellsLiver injuryViral infectionCell-mediated immune responsesBlockade of NKG2DPrimary HBV infectionAcute liver injuryAcute immune responseTransgenic mouse modelPotential therapeutic targetNKG2D-ligand interactionChronic hepatitisHBV infectionAlpha-GalCerNatural killerHepatic pathologyViral antigensMouse modelTherapeutic targetHepatitisCase Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases
Bruce RD, Altice FL. Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases. The American Journal Of Drug And Alcohol Abuse 2007, 33: 869-874. PMID: 17994482, DOI: 10.1080/00952990701653875.Peer-Reviewed Original ResearchConceptsHepatitis C virusAcute hepatitis C infectionHepatitis C infectionBuprenorphine treatmentC infectionChronic viral illnessesSafety of buprenorphineAcute HCV infectionBuprenorphine/naloxoneOpiate substitution therapyOpioid-dependent patientsOpiate substitution treatmentLaboratory evaluationChronic hepatitisElevated transaminasesHCV infectionLiver transaminasesViral illnessCase seriesSubstitution therapyC virusSubstitution treatmentBuprenorphinePatientsTransaminase
2004
Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients
Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas DD. Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. Digestive Diseases And Sciences 2004, 49: 38-41. PMID: 14992432, DOI: 10.1023/b:ddas.0000011599.78222.9e.Peer-Reviewed Original ResearchConceptsDeceased donor transplantationHepatitis C virusLiver transplantationLDLT groupDonor liver transplant recipientsHepatitis C virus recurrenceEnd-stage liver diseaseHCV RNA titersLiver transplant populationLiver transplant recipientsIncidence of rejectionHistological recurrenceChronic hepatitisTransplant recipientsVirus recurrenceDonor transplantationTransplant populationHCV PCRLiver biopsyLiver diseaseAggressive recurrenceSingle pathologistC virusRNA titersInstitutional protocol
1979
Nonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption
Levin D, Baker A, Riddell R, Rochman H, Boyer J. Nonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption. The American Journal Of Medicine 1979, 66: 429-434. PMID: 433949, DOI: 10.1016/0002-9343(79)91064-7.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseNonalcoholic liver diseaseLiver diseaseLiver biopsyHeavy alcohol consumptionAlcohol consumptionHepatitis B surface antigenSerum glutamic oxaloacetic transaminaseB surface antigenGlutamic oxaloacetic transaminaseAcute hepatitisChronic hepatitisTransaminase ratioConsecutive patientsLiver injuryAppropriate therapyClinical featuresLiver disordersOverlooked causeAlcoholic subjectsPatientsSurface antigenOxaloacetic transaminaseBiopsyDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply